While it is still not well understood how PDLIM2 levels or activity are regulated in different tissues or during cancer development or progression, its regulation of key oncogenic signalling pathways suggests strong potential to modulate the tumour microenvironment, at both the level of the tumour cells and associated infiltrating immune cells. The gene discussed is PDLIM2; the disease is cancer.